Evidence of N-acetylcysteine efficacy for skin picking disorder: A retrospective cohort study was written by Hwang, Angelina S.;Campbell, Elliott H.;Sartori-Valinotti, Julio C.. And the article was included in Journal of the American Academy of Dermatology in 2022.SDS of cas: 68-88-2 This article mentions the following:
Skin picking disorder (SPD) is defined as a repetitive skin manipulation, resulting in visible tissue damage and the impairment of social functioning. There have not been consistent pos. responses to previous treatment options, 2 evidence supports the use of N-acetylcysteine (NAC) for SPD. The highest level of evidence comes from a randomized control trial (RCT) with psychiatric endpoints evaluated by psychiatrists. This was a single-center, retrospective study, subjects were identified using the following search terms from medical records on 2 sep. encounters: (acetylcysteine) AND ([picking] OR [acne excoriee] OR [neurodermatitis]). A patient was deemed to have a pos. treatment response if there was an objective improvement documented in the phys. examination and assessment sections of the clin. note. Of 28 participants meeting the inclusion criteria, 85.7% were women, the pos. response rate was 61.5% among 13 patients with an adequate trial (min. dosage of 600 mg twice daily for 3 consecutive months or equivalent dose). The overall response rate (including in those without an adequate trial) was 46.4%. The side effects included gastrointestinal symptoms in 7.1% of the patients, the average age of patients with SPD improvement was 68.5 years vs. 50.9 years of those without improvement. The purpose of our study was to corroborate the results of a previous RCT performed by psychiatrists using predominantly psychiatric end points. Our study focused on dermatol. endpoints observed by dermatologists. In the experiment, the researchers used many compounds, for example, 2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)ethanol (cas: 68-88-2SDS of cas: 68-88-2).
2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)ethanol (cas: 68-88-2) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. SDS of cas: 68-88-2
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics